Guardant Health, Inc. (GH)
| Market Cap | 22.53B +203.8% |
| Revenue (ttm) | 1.18B +42.7% |
| Net Income | -453.44M |
| EPS | -3.50 |
| Shares Out | 134.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,549,234 |
| Open | 161.55 |
| Previous Close | 163.34 |
| Day's Range | 161.55 - 171.74 |
| 52-Week Range | 53.40 - 176.58 |
| Beta | 1.59 |
| Analysts | Strong Buy |
| Price Target | 194.29 (+15.73%) |
| Earnings Date | Jul 30, 2026 |
About GH
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc... [Read more]
Financial Performance
In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $194.29, which is an increase of 15.73% from the latest price.
News
Guardant Health Transcript: Canaccord Genuity's 46th Annual Growth Conference
Strong Q2 2026 results featured rapid growth in core oncology diagnostics, with Shield and Reveal products driving significant volume and revenue gains. Major payer coverage, cost reductions, and expanding clinical indications position the portfolio for continued momentum and broader market impact.
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant's Board of D...
Guardant Health price target raised to $185 from $175 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Guardant Health (GH) to $185 from $175 and keeps an Overweight rating on the shares.
Guardant Health price target raised to $195 from $170 at Stephens
Stephens raised the firm’s price target on Guardant Health (GH) to $195 from $170 and keeps an Overweight rating on the shares. Guardant reported “strong” Q2 results and second half…
Guardant Health price target raised to $193 from $135 at Piper Sandler
Piper Sandler raised the firm’s price target on Guardant Health (GH) to $193 from $135 following quarterly results. The firm keeps an Overweight rating on the shares. Published first on…
Guardant Health price target raised to $180 from $130 at Stifel
Stifel analyst Daniel Arias raised the firm’s price target on Guardant Health (GH) to $180 from $130 and keeps a Buy rating on the shares after “another clean beat and…
Biotech company launches multi-cancer detection test
Guardant Health co-founder and co-CEO Helmy Eltoukhy discusses his company's blood test for colorectal cancer on ‘The Claman Countdown.'
Guardant Health price target raised to $200 from $185 at RBC Capital
RBC Capital analyst Dan Leonard raised the firm’s price target on Guardant Health (GH) to $200 from $185 and keeps an Outperform rating on the shares. The firm cites the…
Guardant Health price target raised to $210 from $200 at TD Cowen
TD Cowen raised the firm’s price target on Guardant Health (GH) to $210 from $200 and keeps a Buy rating on the shares. The firm said expectations were high for…
Guardant Health price target raised to $195 from $190 at BTIG
BTIG raised the firm’s price target on Guardant Health (GH) to $195 from $190 and keeps a Buy rating on the shares. The company drove another strong beat and raise…
Guardant Health price target raised to $195 from $185 at JPMorgan
JPMorgan raised the firm’s price target on Guardant Health (GH) to $195 from $185 and keeps an Overweight rating on the shares.
Guardant Health price target raised to $200 from $175 at Mizuho
Mizuho raised the firm’s price target on Guardant Health (GH) to $200 from $175 and keeps an Outperform rating on the shares.
Guardant Health price target raised to $210 from $185 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Guardant Health (GH) to $210 from $185 and keeps a Buy rating on the shares.
Guardant Health price target raised to $200 from $150 at Barclays
Barclays raised the firm’s price target on Guardant Health (GH) to $200 from $150 and keeps an Overweight rating on the shares. The firm sees a “clear path to more…
Guardant Health files automatic mixed securities shelf
17:32 EDT Guardant Health (GH) files automatic mixed securities shelf
Guardant Health Earnings Call Transcript: Q2 2026
Q2 2026 saw 44% revenue growth to $335M, driven by strong oncology, biopharma, and screening performance. Major milestones included FDA approvals, Shield's inclusion in ACS guidelines, and UnitedHealth coverage, expanding access to 70M lives. Full-year guidance was raised on robust demand and operational efficiency.
Guardant Health Earnings release: Q2 2026
Guardant Health released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Guardant Health Slides: Q2 2026
Guardant Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Guardant Health Quarterly report: Q2 2026
Guardant Health has published its Q2 2026 quarterly earnings report on July 30, 2026.
Guardant Health reports Q2 adjusted EPS (42c), consensus (39c)
Reports Q2 revenue $335M, consensus $314.43M. “Our second-quarter performance reflected broad-based momentum across the Guardant portfolio, with revenue increasing 44% year over year,” said Helmy Elto...
Guardant Health raises FY26 revenue view to $1.34B-$1.36B from $1.3B-$1.32B
Consensus $1.31B. Guardant Health (GH) continues to expect full year 2026 non-GAAP gross margin to be in the range of 64% to 65%. Guardant Health now expects total non-GAAP operating…
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 ...
Guardant Health to Participate in Upcoming Investor Conferences
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. C...
Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of a new video featuring actor and cancer advocate Patrick Demp...
Guardant Health price target raised to $190 from $160 at Guggenheim
Guggenheim raised the firm’s price target on Guardant Health (GH) to $190 from $160 and keeps a Buy rating on the shares. The firm says its Q2 web traffic data…